NeoGenomics (NASDAQ: NEO)
NeoGenomics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
NeoGenomics Company Info
NeoGenomics is a provider of genetic testing, specializing in cancer diagnostics.
News & Analysis
Why Shares of NeoGenomics Jumped Today
The company released promising full-year and fourth-quarter numbers.
Why Shares of NeoGenomics Jumped 53.9% This Week
The cancer screening company showed its turnaround may be working.
3 Top Small-Cap Stocks to Buy Right Now
These under-the-radar names deserve investors' attention.
NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
3 Top Healthcare Stocks to Buy Right Now
These pioneers will be winners however the pandemic plays out.
2 Stocks to Buy and Hold for Decades
Near-term headwinds won’t damage the long-term prospects of these two companies.
The Coronavirus Pandemic Will Test Invitae's Telemedicine Ambitions
Invitae wants to provide medical-grade genetic testing to the masses. Is the business ready for the first big test?
Here's Why NeoGenomics Is Tumbling Today
The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.